[Utilizing the strength(s) of rizatriptan 10 mg: cost effective against migraine attacks].
D000286:Administration, Sublingual; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs / Q000706:statistics & numerical data; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000191:economics*; D016032:Randomized Controlled Trials as Topic; D017366:Serotonin Receptor Agonists / Q000191:economics* / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000191:economics* / Q000627:therapeutic use*; D014363:Tryptamines / Q000191:economics* / Q000627:therapeutic use*
D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan